1月14日晚间，药明生物、药明合联、东曜药业联合发布公告，主体内容是花旗环球金融亚洲有限公司代表要约人药明合联，拟以每股4港元现金收购东曜药业全部已发行股份（除已持有或同意收购部分），并以每股1.7665港元注销全部7,632,600份尚未行使购股权。股份要约价较未受干扰日（2025年12月22日）收盘价2.01港元溢价99%，较30日平均收市价1.86港元溢价114.67%，较经审核净资产...
Source Link1月14日晚间，药明生物、药明合联、东曜药业联合发布公告，主体内容是花旗环球金融亚洲有限公司代表要约人药明合联，拟以每股4港元现金收购东曜药业全部已发行股份（除已持有或同意收购部分），并以每股1.7665港元注销全部7,632,600份尚未行使购股权。股份要约价较未受干扰日（2025年12月22日）收盘价2.01港元溢价99%，较30日平均收市价1.86港元溢价114.67%，较经审核净资产...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.